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Histology findings in idiopathic membranous nephropathy
(MGN) have been associated with the risk of renal failure,
but whether they are independent of the clinical variables
at the time of biopsy, predict rate of progression, or should
guide therapy is uncertain. Renal biopsies of 389 adult
MGN patients were evaluated semiquantitatively for
interstitial fibrosis, tubular atrophy, vascular sclerosis,
focal and segmental glomerulosclerosis lesions (FSGS),
complement deposition, and stage and synchrony of
deposits by electron microscopy (EM). Associations were
tested between these findings and the rate of renal function
decline (slope), renal survival, remission in proteinuria, and
response to immunosuppression. Patients with a greater
degree of tubulo-interstitial disease, vascular sclerosis, and
secondary FSGS were older, had a higher mean arterial
pressure, and a lower creatinine clearance at presentation.
Although these histologic features were associated with a
reduced renal survival, they did not predict this outcome
independently of the baseline clinical variables nor did they
correlate with the rate of decline in function or with baseline
proteinuria. Furthermore, the severity of tubulo-interstitial
and vascular lesions did not preclude a remission in
proteinuria in those who received immunosuppressive
therapy. Neither stage nor synchronicity of EM deposits
nor the amount of complement deposition predicted renal
survival but the latter did correlate with progression rate.
In MGN, certain histologic changes are associated with renal
survival outcome. However, the indicators of chronic injury
are associated with age, blood pressure, and creatinine
clearance at presentation and not with rate of disease
progression or initial proteinuria.
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Idiopathic membranous nephropathy (MGN) is the second
most common cause of end-stage renal disease in the primary
glomerulonephritis group in adults.1 The literature has
consistently reported that the long-term outcome is quite
variable and that reliable early predictors are still needed to
ensure that potent immunosuppressive treatment targets
patients that are at the greatest risk of progression.2–9
The level of renal function, degree of hypertension, and
severity of proteinuria are the most common and routinely
measured clinical predictors. Certain standard histologic
features on renal biopsy have also long been associated with a
poor outcome, particularly the severity of tubulo-interstitial
damage and vascular sclerosis.3,4,6,9–16 A correlation between
the amount of complement deposition on immunofluores-
cence and the severity of proteinuria has also been reported.17
Most recently, the presence of the lesion of focal and
segmental glomerulosclerosis and the findings of hetero-
geneous vs homogeneous (synchronous) morphology of the
subepithelial electron-dense deposits have been linked to a
poor outcome.18–22 Whether these histology features predict
outcome independently of the clinical parameters remains
unclear.
We examined these histologic features and the clinical
findings at the time of renal biopsy to determine their
independent value in predicting outcome in terms of not
only renal survival, but also the rate of progression (slope of
creatinine clearance (CrCl)), remissions in proteinuria, and
on response to therapy.
RESULTS
There were 520 patients with a diagnosis of MGN with
clinical information available in the Toronto Glomerulo-
nephritis registry from 1974 to the end of March 2003.
Exclusions were o12 months follow-up (94), secondary
membranous (20), oage 16 years at presentation (8), and
miscellaneous (9).
The remaining 389 subjects’ baseline characteristics,
follow-up, and outcome are summarized in Table 1. Sixty-
eight percent of patients were male, the average age was 48
years, and patients were followed for a median of 60 months.
Two hundred and twenty patients received immunosuppres-
sive treatment and 50 patients reached renal failure. On
average, the first clinical assessment available predated the
renal biopsy by 2 months. Only 31 patients had their biopsy
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delayed for more than 12 months after the first assessment.
At presentation, their median proteinuria was 3.2 g/day
(0.6–27.0), mean arterial pressure (MAP) was 103714 mmHg,
and CrCl was 71721 ml/min/1.73 m2.
Histology findings are summarized in Table 2. Interstitial
fibrosis and tubular atrophy scores were almost identical and
hence these two features were scored as a single category and
assigned the highest of the two individual scores. Twenty-five
percent of biopsies showed focal and segmental glomerulo-
sclerosis lesions (FSGS) lesions. On EM, 11, 32, 22, and 35%
of biopsies showed stage 1, 2, 3, and 4, respectively, with 48%
showing a homogeneous and 52% showing a heterogeneous
pattern.
The k-score was excellent for FSGS superimposed on
MGN and good for interstitial fibrosis and vascular disease
(k¼ 0.86, 0.67, and 0.60, respectively). Ninety-seven percent
of the interobserver error was by a single grade (i.e. 0 vs 1, 1
vs 2, or 2 vs 3). We used the score from initial biopsy report
in the analyses.
Correlations among the histology findings
Vascular and tubulo-interstitial changes were strongly corre-
lated (spearman’s r 0.50, Po0.001). The presence of FSGS
lesions also correlated with vascular sclerosis and tubulo-
interstitial lesions (spearman’s r of 0.28 and 0.36, respec-
tively, all Po0.001). The amount of C3 deposition showed
no correlation with any of these histology findings.
Tubulo-interstitial disease, vascular sclerosis, FSGS lesions,
and their association with clinical findings
At presentation. Patients with tubulo-interstitial lesions,
vascular sclerosis, and FSGS lesions were older, and had a
higher MAP and a lower CrCl at onset (Table 3). Women had
a higher percent with no fibrosis (48% of women compared
to 35% of men, P¼ 0.02) and no vascular sclerosis (63%
of women compared to 52% of men, P¼ 0.04). In contrast,
no association was seen between these histology findings
and presenting proteinuria: for example, in patients with
48 g/day proteinuria, 24% had Xmoderate tubulo-inter-
stitial fibrosis and 26% had Xmoderate vascular sclerosis
and this was not significantly different from those with
p3.5 g/day at 15 and 25%, respectively (P¼NS, w2).
Race and body mass index at onset were not associated
with any of the light microscopic findings.
During follow-up. The severity of lesions by light micro-
scopy also predicted the MAP during follow-up. The MAP
in those with severe tubulo-interstitial disease was
10579 mmHg with a median of 1 antihypertensive medi-
cation (range 0–3) compared to those with a 0 grade of
9678 mmHg with a median of 0 antihypertensive medica-
tion (range 0–2) (Po0.001, analysis of variance and
Kruskal–Wallis test). The severity of lesions also had an
impact on the class of antihypertensive treatment prescribed
during follow-up. Patients with severe vascular or FSGS
lesions were more likely to receive an angiotensin-converting
enzyme inhibitor (ACEi) or angiotensin receptor blocker
(ARB) during follow-up (46% with FSGS lesions compared
to 33% without such lesions, P¼ 0.05, w2).
The proportion of patients given dual immunosuppres-
sion within each histology group was similar. A total of
14, 16, 18, and 17% of patients with 0, 1þ , 2þ , and
3þ tubulo-interstitial scores were given such therapy and
16, 15, 16, and 16% of patients with 0, 1þ , 2þ , and 3þ
vascular sclerosis scores were so treated. Similarly, 21% of
patients with FSGS lesions vs 13% without these lesions were
given dual therapy (P¼NS, w2).
On outcomes. Renal survival: Tubulo-interstitial and
vascular sclerosis score did predict a lower renal survival
(Figures 1 and 2) with an unadjusted hazard ratio for
severe tubulo-interstitial damage of 5.5 (95% confidence
interval (CI): 2.4–12.8, Po0.001) and for severe vascular
lesions 4.3 (95% CI: 2.0–9.6, Po0.001) in reference to normal
parenchyma. This was not, however, independent of the
CrCl, age, and MAP at biopsy. The hazard ratios for severe
tubulo-interstitial and severe vascular lesions adjusted for
these clinical variables fell to 1.3 (95% CI: 0.4–4.2, P¼NS)
and 1.4 (95% CI: 0.5–4.0, P¼NS), respectively.
The presence of the FSGS lesions produced a trend toward
a lower renal survival (unadjusted hazard ratio: 1.7; 95% CI:
Table 1 | Baseline and follow-up clinical variables (n=389)
At onset
Age (years) 48716
Sex (% female) 33
Ethnicity (%)
Caucasian/African American/Asian/other 70/5/4/10
MAP (mmHg) 102714
CrCl (ml/min/1.73 m2) 76729
Proteinuria (g/day) 4.7 (0.3–31.3)
Follow-up
Duration of follow-up (months) 58 (12–400)
MAP (mmHg) 10079
Proteinuria (g/day) 3.9 (0.3–24.2)
Immunosuppression (%) 56
ACEI or ARB therapy (%) 37
Outcomes
Rate of change in renal functiona 0.3170.68
Renal failure (%) 14
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker;
CrCl: creatinine clearance; MAP: mean arterial pressure.
aMeasured as change in the slope of CrCl (ml/min//1.73 m2/months).
Results are expressed as mean (7s.d.) or median (range).
Table 2 | Histology findings
Score
0 1+ 2+ 3+
Tubulo-interstitial diseasea (%) 34 48 11 7
Vascular sclerosis (%) 46 29 16 9
Complement deposition (C3) (%) 32b 33 22 13
aInterstitial fibrosis and tubular atrophy scores were almost identical. These two
categories were combined and categorized according to the highest score.
b11% were scored negative and 21% were scored trace complement deposition.
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0.9–3.3, P¼ 0.13) but this disappeared after adjusting for the
initial CrCl (Table 2).
Slope: The rate of renal function decline was not predicted
by the amount of vascular or tubulo-interstitial disease or by
the presence of FSGS lesions (Table 5).
Remission in proteinuria: There was no relationship
seen between grade of tubulo-interstitial and vascular
damage and remission in proteinuria in patients treated
with dual immunosuppression, but was seen in untreated
patients (Table 4). Similarly, the presence or absence of
FSGS lesions made no difference in terms of response rate
in treated patients (85 vs 75% respectively, P¼NS), but
in untreated patients, those with FSGS lesions were less
likely to remit (44 vs 68%, P¼ 0.04, w2). No difference in
time elapsed was found from biopsy to remission or from
the start of the immunosuppressive treatment to remis-
sion across the spectrum of histologic changes (data not
shown).
Stage and heterogeneity of deposits by EM
The stage and heterogeneity of deposits did not statistically
correlate with any clinical variables at onset (data not
shown). Patients with a homogeneous pattern were more
likely to achieve a compete remission during follow-up (42%
compared to 20%, P¼ 0.01, w2). However, this was offset by
a 35% relapse rate in the homogeneous compared to 0%
in those with a heterogeneous pattern. Neither stage nor
pattern of deposits predicted rate of renal function decline or
renal survival.
Complement deposition
Baseline clinical variables were similar among different
grades of complement deposition, although proteinuria at
onset tended to be higher in those with X1þ C3 (5.6 g/day,
range 0.3–26.2 g/day) compared to o1þ C3 (4.6 g/day,
range 0.7–16.9 g/day) (P¼ 0.06, Mann–Whitney U-test). The
amount of C3 deposition did correlate with a faster rate
Table 3 | Univariate associations between histology, demographics, and clinical variables at onset
Age at onset MAP Creatinine clearance
Mean (s.d.) P (post hoc)a Mean (s.d.) P (post hoc) Mean (s.d.) P (post hoc)
Fibrosis and tubular atrophy
None (0) 41713 o0.001 97712 o0.001 92723 o0.001
Mild (1) 50715 (0o1, 2, 3) 104713 (0o1, 2, 3) 76726 (0414243)
Moderate (2) 49718 105716 66739 (143)
Severe (3) 52714 106713 48730
Vascular sclerosis
None (0) 41714 o0.001 100712 0.003 90727 o0.001
Mild (1) 51713 (0o1, 2, 3) 102713 (0o2, 3) 76726 (041, 243)
Moderate (2) 54714 106715 (1o3) 77726
Severe (3) 56715 109715 46725
FSGS
None 46715 NS 102714 0.10b 82724 0.006
Present 47716 105714 69738
FSGS: focal and segmental glomerulosclerosis lesions; NS: not significant.
Race and proteinuria at onset were not statistically associated with histology findings. Female patients had less interstitial fibrosis and vascular sclerosis (see text). There was
no statistical association between clinical variables at onset and electron microscopy stage or C3 deposition.
aPost hoc analyses were performed using the least significant difference method to determine specifically which grade was significantly different from another.
bMembranous patients with FSGS lesions were receiving a greater number of antihypertensive medications at presentation (P=0.02, Mann–Whitney test).
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Figure 1 | Renal survival and tubular interstitial disease.
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Figure 2 | Renal survival and vascular sclerosis.
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of renal function decline (X1þ C3: 0.4670.76 vs o1þ
C3: 0.2270.75 ml/min/month, P¼ 0.03 (Table 5)). There
was, however, no difference in renal survival by complement
grade. The unadjusted hazard ratio of renal survival in
those withX1þ C3 in reference to those witho1þ C3 was
1.59 (95% CI: 0.68–3.68, P40.1). No correlation was seen
between degree of complement deposition and remissions in
proteinuria or response to immunosuppressive drugs (data
not shown).
Patients followed for less than 12 months
We reviewed our excluded patients based on o12 months
follow-up time to assess whether this may have biased our
findings. Twenty-seven MGN patients in this group had a
rapid decline in renal function (412 ml/min/1.73 m2/year).
The proportion of the patients with moderate or severe
tubulo-interstitial changes was 22% and those with severe
vascular change was 14%, similar to our study cohort (25 and
18%, respectively).
DISCUSSION
The long-term outcome in idiopathic MGN is highly
variable. The strongest predictors of renal survival in MGN
are the starting glomerular filtration rate and proteinuria.23
Although many studies have previously demonstrated the
importance of histology in predicting the risk of renal
failure,3,4,6,9–22 few have looked at its association with the rate
of renal function decline or performed multivariate analysis
to account for the possible association among histology,
clinical, and laboratory findings at the time of biopsy.
As MGN histology is usually assessed only once, and most
commonly soon after the appearance of symptoms, analyzing
its predictive value must also account for any subsequent
intervention that could alter the natural history of the
disease. The most common and accepted interventions
include blood pressure control, the use of ACEi and/or
ARB class drugs, and immunosuppressive treatment. We
therefore included these three factors in our analyses.
Immunosuppressive therapy was divided in those who recei-
ved no vs dual immunosuppression because the most
recent and best evidence demonstrating the efficacy of such
treatment comes from this approach.24–27
We have confirmed that the severity of tubulo-interstitial
and vascular damage found on light microscopy does predict
renal survival but, of equal or perhaps of more importance,
Table 4 | Ranking histologic findings and remissions in proteinuria (partial or complete) by treatment in nephrotic MGN
patients (n=348)a
Remission,
overall (%) P
Remission without
immunosuppression (%) P
Remission with dual
immunosuppressiona (%) P
Atrophy or fibrosis
0 79 o0.001 84 o0.001 75 NS
1+ 69 59 92
2+ 50 36 57b
3+ 48 33 100b
Vascular sclerosis
0 71 0.06 72 0.02 69 NS
1+ 71 69 75
2+ 58 40 80b
3+ 56 43 100b
MGN: membranous nephropathy.
aExcludes patients who were never nephrotic. Differences between ordered categories were tested with spearman’s rank order. Focal and segmental glomerulosclerosis,
complement deposition, and stage of deposits did not correlate with remission.
bOnly 10 patients with 2 or 3+ tubulo-interstitial or vascular disease received dual immunosuppression.
Table 5 | Univariate associations among severity of histologic
variables and rate of progression (slope) during follow-up
Slopea P
Fibrosis and tubular atrophy
0 0.3270.81 NS
1 0.3070.70
2 0.4370.56
3 0.3170.42
Vascular sclerosis
0 0.3270.74 NS
1 0.3470.66
2 0.2070.53
3 0.3470.58
Segmental sclerosis
0 0.3870.82 NS
1 0.2570.46
Complement deposition
0 or tr 0.2270.75 0.03
X1+ 0.4670.76
Stage
1 0.4670.99 NS
2 0.4570.66
3 0.1770.84
4 0.2070.48
Phase of deposits
Homogeneous 0.3870.71 NS
Heterogeneous 0.2270.68
tr: trace; NS: not significant.
aExpressed in ml/min/1.73 m2/month.
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we found that they do not predict the rate of disease
progression.3,4,6,9–16 The association between the interstitial
and vascular damage and renal survival was accounted for
by a lower starting CrCl and not by a more rapid deterio-
ration in renal function (Table 5 and Figure 3). These
results strengthen the results from our earlier study, which
demonstrated that elderly patients were more likely to
progress to renal failure because of a lower starting CrCl
and not because of the severity of their disease, as they had
an almost identical rate of progression as the younger cohort
as measured by the slope of their CrCl.28
We acknowledge that the error inherent to estimations of
CrCl (instead of direct measurement) may increase the
standard deviations of slopes and lower our statistical power.
Nevertheless, the estimates of CrCl at onset were sufficiently
precise to show clinically meaningful correlation with
histology. In addition, the estimates of slope have previously
allowed us to clearly discriminate patients long-term out-
come in those with or without a remission in proteinuria.23
Further support for the independence of these lesions
from the disease activity is the response to immunosuppres-
sion: in patients treated with dual immunosuppression,
the severity of vascular and tubulo-interstitial lesions had
no effect on remission rate. This indicates that remissions
in proteinuria, valid surrogates of a favorable outcome,23
are possible even in patients with severe degrees of these
lesions. Although the lower rate of spontaneous remission in
patients with tubulo-interstitial, vascular, or FSGS lesions was
interesting, it does not, by itself, justify immunosuppressive
therapy.
It could be argued that the variation in the degree of
renal scarring may reflect the impact of chronicity of the
membranous disease per se, but the lack of association
between these changes and the post-biopsy progression rate,
that is, slope, suggests that this is unlikely unless the natural
history has been modified by subsequent therapy. We did not
find this to be the case but found that the degree of tubulo-
interstitial and vascular scarring only correlated with sex, age,
and blood pressure at presentation. These factors have very
recently been shown to be closely linked to renal function in
‘normal’ patients being assessed for living kidney donation
with no specific renal disease.29 This supports our contention
that age and prior blood pressure level are the basis for the
majority of the chronic injury observed at the time of biopsy.
The dichotomy between severity of tissue injury associated
with age, hypertension, and the presenting CrCl but not with
the subsequent rate of renal function decline or severity of
presenting proteinuria, was of major interest to us. Although
other studies have found a correlation between tissue scarring
and proteinuria at biopsy, the strength of this association was
weak (r2B10%).30 Our interpretation is that pre-existing
factors in the patient are primarily responsible for these
lesions and they in turn result in a lower presenting CrCl.
The severity of the membranous disease in contrast would
appear to be best reflected by the severity of proteinuria and
subsequent rate of deterioration in renal function, that is,
slope of CrCl.23 Whether the time and quality of life gained
related to prolonged renal survival time with a remission is
worth the risk of such therapy in a patient with under-
lying scarring and already impaired renal function is a
separate question and cannot be answered by this study. This
interpretation is further supported by recent studies showing
that immunosuppressive treatment can be effective in redu-
cing proteinuria and stabilizing glomerular filtration rate
even in MGN patients with significant impairment of renal
function.31,32
Other points relating renal histologic changes and out-
come are also noteworthy. The lesions of focal and segmental
glomerulosclerosis in MGN have been linked to a worse
prognosis.15,18–21 Although we also found a trend toward a
reduced renal survival in MGN patients with added FSGS
lesions, this group had a lower initial CrCl, largely explaining
their lower renal survival. Importantly, this group was not
different in factors we associate more severe disease with,
that is, presenting proteinuria and/or progression rate (Tables
3 and 5).
The predictive value of the stage of the deposits on elec-
tron microscopy (EM) varies, with some positive3,6,9,11,33–35
and some negative.10,36–39 A recent retrospective study of 105
patients further suggested that a heterogeneous pattern was
an independent predictor of end-stage renal disease.22 We
looked at both stage and heterogeneity of deposits and found
that neither was predictive of rate of decline or of renal
survival. We did find however that dividing the patients into
homogeneous and heterogeneous deposits can be difficult,
particularly with regard to separating the patient into pure
stage 2 or 3 vs a 2–3 overlap.
Perhaps of most interest, the only histology finding
predicting rate of renal function deterioration was the
amount of complement deposition. Certainly, there is strong
support from animal MGN models that complement acti-
vation is a prerequisite for the development of tissue injury
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Figure 3 | An illustration of the relationship between light
microscopy findings, CrCl at time of biopsy, rate of renal function
decline, and renal survival in MGN. Patient 1 with significant
indicators of chronic tissue injury by light microscopy has a lower
CrCl at time of biopsy (Y axis) and a reduced renal survival time
(X axis) in comparison to patient 2 with no chronic changes, a
higher starting CrCl, and longer survival time despite a similar rate
of renal function decline.
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and subsequent proteinuria.34–36 Our data would also fit
with earlier human studies suggesting that the membrane
attack complex, the end product of complement activation,
is increased in patients with the most severe and progressive
variants of MGN. Although our results do support a link
between quantitative complement deposition and progres-
sion, we are cautious in drawing too definitive a conclusion
from this association considering the limited number of
patients, the semiquantitative and unverified grading system,
and the variations in reagent specificity used to estimate
complement deposition over the last three decades. An addi-
tional concern about this finding is the lack of association
with our other outcome, renal survival.
Finally, we reviewed the pathology of those who had a
rapid progression but were excluded because ofo12 months
observation. Our concern was if this group had a higher
proportion with severe tubulo-interstitial and vascular
disease, this would introduce a bias in our overall results by
excluding the patients with severe tubular interstitial and/or
vascular changes and rapid progression from our analysis. We
found no difference in the percentage with severe changes
between this group and our overall cohort, further strength-
ening our opinion that the grade of these features does not
reflect membranous disease severity.
In conclusion, in adult MGN patients, certain histology
findings by light microscopy do predict the likelihood of
renal failure but they are more closely linked to pre-existing
and often nonmodifiable factors such as age and sex rather
than to proteinuria and rate of deterioration, our current best
indicators of membranous disease severity. The introduction
of the concept of separating pre-existing changes from those
that reflect MGN disease severity should lead to a new
perspective in assessing the clinical pathological correlates
and treatment timing in this disorder.
MATERIALS AND METHODS
All idiopathic adult MGN patients from the Toronto Glomerulo-
nephritis Registry were considered. This database began in 1974
and includes all biopsy-proven cases of glomerulonephritis from
the Toronto area. Patient information at onset is compiled using
a standard form and registrars perform a periodic prospective
assessment of the patient’s clinical status, medication, and labora-
tory results. This study focuses on MGN patients older than 16 years
at presentation with at least 12 months follow-up.
Parameters collected
Demographics included age, sex, race, and body mass index at
presentation. Clinical and laboratory data collected included both
initial and follow-up information on systolic and diastolic blood
pressure, weight, serum creatinine, and 24 h urine protein and
creatinine. Also recorded was exposure to immunosuppressive
agents and antihypertensive medications including the ACEi and
ARB drug classes.
Definitions
All pathology reports were independently reviewed by two of the
authors, masked to the clinical data (LR, ST). They assessed the
following features on light microscopy: degree of interstitial fibrosis,
tubular atrophy, vascular sclerosis, and the presence of FSGS. Sixty
of these patients had their light microscopy slides reviewed
independently by a third author (AH), masked to the clinical data,
who also graded the vascular sclerosis and the amount of interstitial
fibrosis and tubular atrophy as absent (0), mild (1þ )¼o25%,
moderate (2þ )¼ 25–50%, or severe (3þ )¼450% of parenchy-
ma. The final score for degree of vascular sclerosis was based on
the most severe disease seen in either arterioles or arteries. Arteries
were graded by the highest degree of damage in an affected artery
not cut tangentially. Grading of the arteries was made as follows:
mild was intimal thickening less than the diameter of the lumen or
the thickness of the media, moderate was intimal thickening
approximately the same as the diameter of the lumen or the
thickness of the media, and severe was intimal thickening
significantly greater than the diameter of the lumen or the thickness
of the media causing significant luminal narrowing. Arterioles were
graded as hyalinosis of the most affected arterioles as mild (mural
hyalinosis causing no narrowing and width of hyalinosis signi-
ficantly less than the medial thickness), moderate (mural hyalinosis
causing some narrowing and width of hyalinosis is transmural), and
severe (transmural hyalinosis causing significant luminal narrow-
ing). Focal glomerulosclerosis in MGN was defined as the presence
of segmental sclerosis or capillary collapse with or without capillary
adhesions to the capsule or segmental hyalinosis19 and graded
present or absent. A minimum of 10 glomeruli per biopsy were
required before assigning a negative score to that patient. A k-score
was determined for each of the light microscopic parameters.
The amount of C3 deposition on immunofluorescence was
graded semiquantitatively as absent (0), trace (tr), mild (1þ ),
moderate (2þ ), or severe (3þ ). Deposits were staged by EM from
1 to 4 according to the Ehrenreich and Churg40 classification and
assigned the most advanced stage if more than one stage was
present. In addition, we considered the deposits as synchronous
(homogeneous) when they were all at any one stage, and hetero-
geneous when distributed in two or more stages.22 All the original
EM photographs were also reviewed by our nephropathologist
(AH), the stage reassessed, and deposits classified as homogeneous
or heterogeneous.
CrCl estimates were adjusted for age, sex, and weight using
the Cockcroft–Gault method. Nephrotic patients were identified
by a proteinuria value X3.5 g/day at any point during follow-up.
A compete remission of proteinuria was defined by a single protein-
uria value p0.3 g/day in a previously nephrotic patient. A partial
remission was defined by a proteinuria value o3.5 and 40.3 g/day
plus a 50% reduction from its peak value. Subjects who had both a
partial remission and a compete remission were only included in the
compete remission group and time to remission was calculated from
the first clinical assessment suggestive of renal disease (abnormal
proteinuria or serum creatinine). Renal failure was defined by a CrCl
p15 ml/min or by initiation of dialysis. MAP was estimated as the
diastolic pressure plus a third of the pulse pressure. For each patient,
an average MAP was determined for each 6-month period of follow-
up. Time-average MAP represents the average of their 6 months
means. Immunosuppressive treatment is reported as intent to treat
regardless of the duration of therapy. Patients are categorized as
having received no, mono-, or dual immunosuppressive therapy
(10). This last group was defined by a minimum of 10 mg of
prednisone plus at least 1.5 mg/kg of azathioprine or cyclosporine
or 1 mg/kg of cyclophosphamide or 0.15 mg/kg of chlorambucil or
1000 mg of mycophenolate mofetil. Monotherapy was defined as
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exposure to any form of immunosuppressive treatment that did
not satisfy the dual therapy definition (e.g. steroids alone). Therapy
with ACEi or ARB is defined as any exposure to these classes
of drugs.
Statistical analysis
Normally distributed variables were expressed as mean7standard
deviation and compared using Student’s t-test, one-way analysis of
variance or Pearson test. Nonparametric continuous variables were
expressed as median and range and compared using either
Mann–Whitney or Kruskal–Wallis test. Categorical variables were
expressed in percentage and compared using w2 test. Correlations
between ordered categories were performed using Spearman’s
r coefficient. Agreement between the reviewers of the pathology
was assessed using the k statistic.41
The rate of renal function decline (slope) and survival from renal
failure were the two definitive outcomes. The slope was determined
by fitting a straight line through the calculated CrCl values on each
patient using the principle of least squares. This was plotted and
visually examined in all subjects. Periods of reversible acute renal
failure defined as a rapid reduction and recovery in CrCl of X40%
within a month were censored. Multiple linear regression was
used to determine independent variables predictive of slope. Only
variables associated by univariate analysis were included in a
multivariate model.
Survival analysis was performed to test the association between
renal survival and each parameter collected. Survival times
were obtained from first to last follow-up or the time to renal
failure. Univariate comparisons of renal survival were performed
by Kaplan–Meier curves and log-rank test. A multivariate Cox pro-
portional hazard model was constructed to determine independent
variables associated with this outcome.
All P-values were two-tailed and values less than 0.05 were
considered statistically significant. CI included 95% of predicted
values. Analyses were carried out using SPSS software (version 11,
SPSS Inc., Chicago, IL, USA).
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